Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study

Athens, Greece — January 30, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.  ANAVEX 2-73 is scheduled to commence Phase 1 studies in 2009. “The agreement…

Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology

Athens, Greece — December 17, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition…

Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

Athens, Greece — December 4, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society…

Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate

Athens, Greece — September 2, 2008 Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist…

Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008

Chicago, Illinois — July 30, 2008 — ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today presented data from the company’s novel compound, ANAVEX 1-41, targeting Alzheimer’s disease, at the International Conference on Alzheimer’s Disease (ICAD)…

Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA)

Athens, Greece — June 24, 2008 — Anavex Life Sciences Corp.  (“ANAVEX”) (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer’s Disease 2008 (July 26–31, 2008,Chicago,USA), where it will present results obtained with ANAVEX 1-41 demonstrating a protective effect against the neurotoxicity of amyloid β25-35 peptide (Aβ25-35) in mice.  This peptide is used…

Anavex Announces Appointment of Oncology Specialist to Board of Directors

Athens, Greece — May 21, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTC BB:AVXL) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer (NYSE:PFE), with responsibility for Pfizer’s oncology portfolio, which includes more than 20 drug candidates in clinical development,…

ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity

Geneva, Switzerland — March 10, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.  The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering…